Selective Glucocorticoid Receptor Modulators (SGRMs) delay castrate-resistant prostate cancer growth

Molecular Cancer Therapeutics

Volumn 16, Issue 8, 2017, Pages 1680-1692

  Kach, Jacob ^a   Long, Tiha M ^a   Selman, Phillip ^a   Tonsing Carter, Eva Y ^a   Bacalao, Maria A ^a   Lastra, Ricardo R ^a   De Wet, Larischa ^a   Comiskey, Shane ^a   Gillard, Marc ^a   VanOpstall, Calvin ^a   West, Diana C ^a   Chan, Wen Ching ^a   Vander Griend, Donald ^a   Conzen, Suzanne D ^a,b   Szmulewitz, Russell Z ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKAP12 PROTEIN; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; BETA ACTIN; CEBPD PROTEIN; CORT 108297; CORT 118335; DEXAMETHASONE; ENZALUTAMIDE; FKBP5 PROTEIN; GLUCOCORTICOID RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR BETA; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HORMONE RECEPTOR STIMULATING AGENT; KLK3 PROTEIN; MESSENGER RNA; METRIBOLONE; MIFEPRISTONE; PEPTIDES AND PROTEINS; PROSTATE SPECIFIC ANTIGEN; PROTEIN; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; STEROID HORMONE RECEPTOR BLOCKING AGENT; TRANSCRIPTOME; TUMOR MARKER; UNCLASSIFIED DRUG; ZBTB16 PROTEIN; GLUCOCORTICOID RECEPTOR; PHENYLTHIOHYDANTOIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; TUMOR XENOGRAFT; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOLECULAR LIBRARY; NUDE MOUSE; PATHOLOGY; PHARMACOLOGY; THERAPEUTIC USE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE, NUDE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; TRANSCRIPTION, GENETIC;

EID: 85027112449     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0923     Document Type: Article

References (48)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30.
2. Huggins C, Stevens RJ, Hodges C. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Archiv Surg 1941;43:209–23.
3. Vogelzang N. Comprehensive textbook of genitourinary oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.
4. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187–97.
5. Kregel S, Chen JL, Tom W, Krishnan V, Kach J, Brechka H, et al. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. Oncotarget 2016;7: 26259–74.
6. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997;11:450–9.
7. Romanel A, Gasi Tandefelt D, Conteduca V, Jayaram A, Casiraghi N, Wetterskog D, et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med 2015;7:312re10.
8. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69:16–22.
9. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19:575–86.
10. Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 2016;22:298–305.
11. Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer 2014;5:72–89.
12. Arora Vivek K, Schenkein E, Murali R, Subudhi Sumit K, Wongvipat J, Balbas Minna D, et al. Glucocorticoid receptor confers resistance to anti-androgens by bypassing androgen receptor blockade. Cell 2013;155: 1309–22.
13. Kach J, Conzen SD, Szmulewitz RZ. Targeting the glucocorticoid receptor in breast and prostate cancers. Sci Transl Med 2015;7:305ps19.
14. Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T, et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 2001;93:1739–46.
15. Smith RG, Syms AJ, Nag A, Lerner S, Norris JS. Mechanism of the glucocorticoid regulation of growth of the androgen-sensitive prostate-derived R3327H-G8-A1 tumor cell line. J Biol Chem 1985;260: 12454–63.
16. Yan TZ, Jin FS, Xie LP, Li LC. Relationship between glucocorticoid receptor signal pathway and androgen-independent prostate cancer. Urol Int 2008;81:228–33.
17. Tieszen CR, Goyeneche AA, Brandhagen BN, Ortbahn CT, Telleria CM. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC Cancer 2011;11:207.
18. Lin MF, Kawachi MH, Stallcup MR, Grunberg SM, Lin FF. Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone. Prostate 1995;26:194–204.
19. Gabaglia CR, DeLaney A, Gee J, Halder R, Graham FL, Gauldie J, et al. Treatment combining RU486 and Ad5IL-12 vector attenuates the growth of experimentally formed prostate tumors and induces changes in the sentinel lymph nodes of mice. J Transl Med 2010;8:98.
20. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989;7:590–7.
21. Fakih M, Johnson CS, Trump DL. Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology 2002;60: 553–61.
22. Szmulewitz RZ, Clark R, Lotan T, Otto K, Taylor Veneris J, Macleod K, et al. MKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression. Int J Cancer 2012;130:509–20.
23. Yemelyanov A, Bhalla P, Yang X, Ugolkov A, Iwadate K, Karseladze A, et al. Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality. Cell Cycle 2012;11:395–406.
24. Bolton EC, So AY, Chaivorapol C, Haqq CM, Li H, Yamamoto KR. Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev 2007;21:2005–17.
25. Cleutjens CB, Steketee K, van Eekelen CC, van der Korput JA, Brinkmann AO, Trapman J. Both androgen receptor and glucocorticoid receptor are able to induce prostate-specific antigen expression, but differ in their growth-stimulating properties of LNCaP cells. Endocrinology 1997;138: 5293–300.
26. Clark RD. Glucocorticoid receptor antagonists. Curr Top Med Chem 2008;8:813–38.
27. Song LN, Coghlan M, Gelmann EP. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol Endocrinol 2004;18:70–85.
28. Clark RD, Ray NC, Williams K, Blaney P, Ward S, Crackett PH, et al. 1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity. Bioorg Med Chem Lett 2008;18:1312–7.
29. Hunt HJ, Ray NC, Hynd G, Sutton J, Sajad M, O'Connor E, et al. Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat. Bioorg Med Chem Lett 2012;22:7376–80.
30. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 2004;64:1757–64.
31. Michiel Sedelaar JP, Dalrymple SS, Isaacs JT. Of mice and men–warning: intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively. Prostate 2013;73:1316–25.
32. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997;3:402–8.
33. Schilling K, Liao S. The use of radioactive 7 alpha, 17 alpha-dimethyl-19-nortestosterone (mibolerone) in the assay of androgen receptors. Prostate 1984;5:581–8.
34. Sherk AB, Frigo DE, Schnackenberg CG, Bray JD, Laping NJ, Trizna W, et al. Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. Cancer Res 2008;68:7475–83.
35. Xie N, Cheng H, Lin D, Liu L, Yang O, Jia L, et al. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. Int J Cancer 2015;136:E27–38.
36. Wallace AD, Cao Y, Chandramouleeswaran S, Cidlowski JA. Lysine 419 targets human glucocorticoid receptor for proteasomal degradation. Steroids 2010;75:1016–23.
37. Vedeckis WV, Ali M, Allen HR. Regulation of glucocorticoid receptor protein and mRNA levels. Cancer Res 1989;49(8 Suppl):2295s–302s.
38. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 2010;107:16759–65.
39. Szmulewitz RZ, Chung E, Al-Ahmadie H, Daniel S, Kocherginsky M, Razmaria A, et al. Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate 2012;72:157–64.
40. Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall BA, Cai Y, et al. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res 2013;19:6163–72.
41. Heikinheimo O, Kekkonen R, Lahteenmaki P. The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. Contraception 2003;68:421–6.
42. Mammi C, Marzolla V, Armani A, Feraco A, Antelmi A, Maslak E, et al. A novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet. Int J Obes 2016;40:964–72.
43. Masson MJ, Collins LA, Carpenter LD, Graf ML, Ryan PM, Bourdi M, et al. Pathologic role of stressed-induced glucocorticoids in drug-induced liver injury in mice. Biochem Biophys Res Commun 2010;397:453–8.
44. Gibbons JA, de Vries M, Krauwinkel W, Ohtsu Y, Noukens J, van der Walt JS, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet 2015;54:1057–69.
45. Wang D, Muller N, McPherson KG, Reichardt HM. Glucocorticoids engage different signal transduction pathways to induce apoptosis in thymocytes and mature T cells. J Immunol 2006;176:1695–702.
46. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028–38.
47. Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2016;2:1441–9.
48. Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, et al. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int 2008;101:1084–9.